风险建模以减少对自身抗体阳性人群的监测以预防1型糖尿病诊断时的糖尿病酮症酸中毒
基于TrialNet Pathway to Prevention研究(2004年3月至2019年4月,6193例自身抗体阳性个体),建立儿童与成人单抗体或多抗体人群进展至临床诊断的模型,以估计风险率并确定最优监测访视计划。将常规研究监测访视次数减半可能大幅降低1型糖尿病诊断时糖尿病酮症酸中毒的人群发生率。
要点
- 自身抗体阳性人群每6个月代谢监测可降低诊断时糖尿病酮症酸中毒发生率。
- 将常规研究监测访视次数减半可能大幅降低诊断时糖尿病酮症酸中毒的人群发生率。
- 减少监测访视可减轻临床负担,提示可将监测从研究环境过渡到临床环境。
核心结论
- 将常规研究监测访视次数减半可能大幅降低1型糖尿病诊断时糖尿病酮症酸中毒的人群发生率。
研究设计与样本
- 对TrialNet Pathway to Prevention(PTP)研究数据的分析,PTP是一项识别并随访1型糖尿病患者高危亲属的横断面纵向研究,为基于人群的研究,在多个国家招募。
- 2004年3月至2019年4月期间,共6193例自身抗体(AAB)阳性个体参与PTP。
- 为儿童和成人单抗体或多抗体人群建立进展至临床诊断的模型,并用估计的风险率总结结果。
- 为每个模型确定最优监测访视计划,以达到各人群未诊断时间的最低平均水平。
主要发现
- 将常规研究监测访视次数减半可能大幅降低1型糖尿病诊断时糖尿病酮症酸中毒的人群发生率。
临床怎么用
- 作者认为,减少监测访视可减轻临床负担,提示可将监测从研究环境过渡到临床环境。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: The presence of islet autoimmunity identifies individuals likely to progress to clinical type 1 diabetes (T1D). In clinical research studies, autoantibody screening followed by regular metabolic monitoring every 6 months reduces incidence of diabetic ketoacidosis (DKA) at diagnosis. OBJECTIVE: We hypothesized that DKA reduction can be achieved on a population basis with a reduced frequency of metabolic monitoring visits. We reasoned that prolonged time between the development of T1D and the time of clinical diagnosis ("undiagnosed time") would more commonly result in DKA and thus that limiting undiagnosed time would decrease DKA. METHODS: An analysis was conducted of data from TrialNet's Pathway to Prevention (PTP), a cross-sectional longitudinal study that identifies and follows at-risk relatives of people with T1D. PTP is a population-based study enrolling across multiple countries. A total of 6193 autoantibody (AAB)-positive individuals participated in PTP from March 2004 to April 2019. We developed models of progression to clinical diagnosis for pediatric and adult populations with single or multiple AAB, and summarized results using estimated hazard rate. An optimal monitoring visit schedule was determined for each model to achieve a minimum average level of undiagnosed time for each population. RESULTS: Halving the number of monitoring visits usually conducted in research studies is likely to substantially lower the population incidence of DKA at diagnosis of T1D. CONCLUSION: Our study has clinical implications for the metabolic monitoring of at-risk individuals. Fewer monitoring visits would reduce the clinical burden, suggesting a path toward transitioning monitoring beyond the research setting.
引用
- O'Rourke C, Ylescupidez A, Bahnson HT, et al. Risk Modeling to Reduce Monitoring of an Autoantibody-Positive Population to Prevent DKA at Type 1 Diabetes Diagnosis. J Clin Endocrinol Metab. 2023. PMID: 36227635. doi:10.1210/clinem/dgac594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。